Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aristotle University Of Thessaloniki
Age
29–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Primary open-angle glaucoma or exfoliative glaucoma
Patients who require additional IOP lowering on latanoprost monotherapy
Morning IOP greater than 20 mm Hg on latanoprost monotherapy
Untreated morning IOP greater than 26 mm Hg
Patients older than 29 years
Patients with early to moderate glaucoma (less than 14 decibel (dB) mean deviation visual field loss attributed to glaucoma and 0.8 or better vertical cup-to-disc ratio)
On therapy with latanoprost monotherapy for at least 3 months
Patients with a reliable visual field
Best corrected distance Snellen visual acuity \>1/10
Corneal pachymetry within the 550 ± 50 μm range
Patients should understand the study instructions
Patients willing to attend all follow-up appointments and willing to comply with study medication usage
Patients who have open, normal appearing angles
You may not be if
History of combined topical therapy
Contraindication to prostaglandins or timolol
History of ocular trauma or inflammation; intraocular surgery; severe dry eyes; use of contact lenses
Sign of ocular infection except for mild blepharitis
Any corneal abnormality that could have affected the measurement of IOP
Chronic use of topical corticosteroids in the last 3 months before entering the study
Current, or previous use of systemic corticosteroid treatment
Uncontrolled systemic disease
Change of a systemic medication during the study period
Women of childbearing potential or lactating mothers
Inability to understand the instructions and adhere to medications
Clareo Health | Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination Therapy
